Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BNT162b2 immunogenicity and safety in adults with or without prior SARS-CoV-2 infection
2021-000509-26Phase 2Completed
- Sponsor
- Inserm-ANRS
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Inserm-ANRS. Primary endpoint: Anti-SARS-CoV-2 Spike IgG. Started Feb 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000509-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000509-26.